First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

By Aogi Kenjiro   Masuda Norikazu   Ohno Shinji   Oda Takashi   Iwata Hiroji   Kashiwaba Masahiro   Fujiwara Yasuhiro   Kamigaki Shunji   Ito Yoshinori   Ueno Takayuki   Takashima Shigemitsu  

Breast Cancer Research and Treatment, Vol. 129, Iss. 3, 2011-10 ,pp. : 829-838

Springer Publishing Company

Access to resources Recommend Favorite

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

By Lobo Christopher   Lopes Gilberto   Baez Odalys   Castrellon Aurelio   Ferrell Annapoorna   Higgins Connie   Hurley Erin   Hurley Judith   Reis Isildinha   Richman Stephen   Seo Pearl   Silva Orlando   Slingerland Joyce   Tukia Keleni   Welsh Catherine   Glück Stefan  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 427-435

Springer Publishing Company

Access to resources Recommend Favorite

A window‐of‐opportunity biomarker study of etodolac in resectable breast cancer

By  

Cancer Medicine, Vol. 2045-7634, Iss. 10, 2015-10 ,pp. : 1583-1588

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials

By Valachis A.   Polyzos N.   Patsopoulos N.   Georgoulias V.   Mavroudis D.   Mauri D.  

Breast Cancer Research and Treatment, Vol. 122, Iss. 1, 2010-07 ,pp. : 1-7

Springer Publishing Company

Access to resources Recommend Favorite

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

By Brufsky Adam  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1067-1075

Springer Publishing Company

Access to resources Recommend Favorite